Quetiapine의 정신분열증에 대한 효능 및 안전성에 관한 개방 연구 = Open clinical trial to assess the efficacyand safety of quetiapine in patients of schizophrenia

다국어 초록 (Multilingual Abstract)

Objective: The efficacy, tolerability and safety of quetiapine in schizophrenia patients diagnosed by the diagnostic criteria of schizophrenia of the Diagnostic Statistical Manual 4th edition(APA) was studied in psychiatric department of 4 hospital in Korea.
Methods: Sixty-four patients (male 31, female 33; age 34.2±10.4 years; illness duration 8.1±8.3 years) who showed acute exacerbation, partial response, or intolerable adverse event to previous antipsychotic drugs were recruited. Doses of quetiapine were adjusted to maximize efficacy and minimize adverse events. Efficacy was assessed by the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scale. Tolerability and safety were assessed by reports of adverse events, clinically significant abnormal laboratory values and changes from the baseline to week 8 in the Abnormal Involuntary Movement Scale (AIMS) and Simpson-Angus total score as index of extrapyramidal symptoms (EPS).
Results: Fifty-three patients completed the 8 weeks trial. The clinical symptoms indexed by BPRS were significantly improved(baseline score = 37.9±13.0, score at the end = 24.3±13.6; F = 41.5, d.f. = 2.4, p = 0.000). The CGI score of severity of illness was also significantly reduced (baseline score = 4.7±1.1, score at the end = 3.6±1.2; F = 27.6, d.f. = 2.2, p = 0.000). The frequencies of the worsening of AIMS and Simpson-Angus scores at the end of study were 7.5% and 4.2%, respectively. The most common adverse events of at least moderate intensity were EPS(9.3%), constipation(6.3%), and sedation(4.7%).
Conclusions: The results of this study suggest that quetiapine is effective, may have a favorable EPS, and has overall safe tolerability in the patients with schizophrenia, and schizophreniform disorder.

참고문헌 (Reference)

1 "이홍식이희상남궁기김찬형최낙경도정호 등. 치료저항 정신분열증 환자에서의 clozapine 효과. 대한정신약물학회지 1993" 161-168,

2 Arch Gen Psychiatry 1974, "Van Puten T. Why do schizophrenic patients refuse to take their drugs" 67-72,

3 Overal JE, "The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling" 24 : 97-99, 198

4 Meltzer HY, "Sh-arpe J. A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology" 67-72, 1989

5 "Risperidone in treatment-refractory schizophrenia." 156 : 1374-1379, 1999

6 "Ris-peridone versus clozapine in treatment-resistant chronic schizo-phrenia: a randomized double-blind study" 155 : 499-504, 1998

7 Small JG, "Quetiapine in patients with schizo-phrenia a high- and low-dose double-blind comparison with placebo." 54 : 549-557, 197

8 "Quetiapine for schizophrenia(Cochrane review)." Oxford, The Cochrane Library 2003

9 "Optimizing dosing of atypical antipsychotics in adults: a review of the current evidence" 10 : 280-291, 2002

10 "Olanzapine versus haloperidol treatment in first-episode psychosis." 156 : 79-87, 1999

11 "Olanzapine versus haloperidol in the treat-ment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial" 154 : 457-465, 197

12 Arvanitis LA, "Multiple fixed doses of 'Seroquel in patients with acute exacerbation of schizophrenia a comparison with halo-peridol and pacebo" 42 : 233-246, 1997

13 Schizophr Res 1989, "Meltzer HY. The role of serotonin in the mechanism of action of antipsychotic drugs Dose 5-HT also have a role in the etiology of schizophrenia" 212-,

14 "Kane JM. The curent status of neuroleptic therapy. J Clin Psy-chiatry 1989" 322-328,

15 Borison RL, "ICI 204,636, an atypical antipsychotic: eficacy and sa-fety in a multicenter, placebo-controlled trial in patients with schizophrenia" 16 : 158-169, 1996

16 "Gerlach J. Tolerability and therapeutic efect of clozapine A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psy-chiatr Scand 1985" (ring v) : 176-185,

17 "Dosing and switching strategies for quetiapine fumarate." 24 : 209-222, 2002

18 Kane J, "Clozapine for the treatment-resistant sc-hizophrenia A double-blind comparison with chlorpromazine" 45 : 789-796, 198

19 "Assessment Manual for Psychopharmacology US Department of Health" 1976218-222,

20 Seeman P, "Antipsychotic drugs, dopamine receptors, and schizo-phrenia" 1 : 53-60, 2001

21 "Angus JW. A rating scale for extrapyramidal side efects. Acta Psychiatr Scand" 11-19, 1970

22 4th ed, "American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders" 1994.

23 "Abnormal involuntary movement scale. In ECDEU Assessment Manual for Psychopharmacology US Department of Health" 1976.

24 Mullen J, "A comparison of the relative safety and tolerability of Quetiapine and Risperidone in outpatients with schizophrenia and other psychotic disorders the Quetiapine experience with safety and tolerability(QUEST) study" 23 : 1839-1854, 201